Psychiatric issues in chronic pain

Current Psychiatry Reports

Volumn 11, Issue 3, 2009, Pages 243-250

  Clark, Michael R ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLONIDINE; DESVENLAFAXINE; DULOXETINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; HARKOSERIDE; LAMOTRIGINE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; PIMOZIDE; PLACEBO; PREGABALIN; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ALLODYNIA; ANALGESIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; BRAIN DISEASE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; FACE PAIN; FIBROMYALGIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; IRRITABLE COLON; LIFE EVENT; LOW BACK PAIN; MAJOR DEPRESSION; MENTAL DISEASE; MIGRAINE; NEUROPATHIC PAIN; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SOMATIZATION; SOMATOFORM DISORDER; SUBSTANCE ABUSE; TENSION HEADACHE; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADAPTATION, PSYCHOLOGICAL; CHRONIC DISEASE; COMORBIDITY; HUMANS; MENTAL DISORDERS; PAIN; PATIENT CARE TEAM; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 65749094949     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-009-0037-6     Document Type: Review

References (81)

1. McHugh PR, Clark MR: Diagnostic and classificatory dilemmas. In Psychosomatic Medicine in the 21st Century. Edited by Blumenfield M, Strain JJ. Baltimore, MD: Lippincott Williams & Wilkins; 2006:39-45.
2. Clark MR: PsychogAnic disorders: a pragmatic approach for formulation and treatment. Semin Neurol 2006, 26:357-365.
3. Kirmayer LJ, Groleau D, Looper KJ, et al.: Explaining medically unexplained symptoms. Can J Psychiatry 2004, 49:663-672.
4. Brown RJ: Psychological mechanisms of medically unexplAined symptoms: an integrative conceptual model. Psychol Bull 2004, 130:793-812.
5. Rief W, Barsky AJ: Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 2005, 30:996-1002.
6. McHugh PR, Slavney PR: Methods of rCasoning in psychopathology: conflict and resolution. Compr Psychiatry 1982, 23:197-215.
7. McHugh PR: A structure for psychiatry at the century's turn-the view from Johns Hopkins. J R Soc Med 1992, 85:483-487.
8. McHugh PR, Slavney PR: Perspectives of Psychiatry, edn 2. Baltimore, MD: The Johns Hopkins University Press; 1998.
9. Slavney PR: Perspectives on "Hysteria." Baltimore, MD: The Johns Hopkins University Press; 1990.
10. Reuber M, Mitchell AJ, Howlett SJ, et al.: Functional symptoms in neurology: Questions and answers. J Neurol Neurosurg Psychiatry 2005, 76:307-314.
11. Clark MR, Treisman GJ: Perspectives on pain and depression. Adv Psychosom Med 2004, 25:1-27.
12. Stone J, Carson A, Sharpe M: Functional symptoms and signs in neurology: management. J Neurol Neurosurg Psychiatry 2005, 76(Suppl 1):i13-i21.
13. Rief W, Nanke A: Somatoform disorders in primary care and inpatient settings. Adv Psychosom Med 2004, 26:144-158.
14. Larson SL, Clark MR, Eaton WW: Depressive disorder as a long-term antecedent risk factor for incident back pain: A 13-year follow-up study from the Baltimore Epidemiological Catchment Area sample. Psychol Med 2004, 34:211-219.
15. Schieir O, Thombs BD, Hudson M, et al.: Symptoms of depression predict the trajectory of pain among patients with early inflammatory arthritis: a path analysis approach to assessing change. J Rheumatol 2009, 36:231-239.
16. Dersh J, Polatin PB, Gatchel RJ: Chronic pain and psychopathology: research findings and theoretical considerations. Psychosom Med 2002, 64:773-786.
17. Rahman A, Reed E, Underwood M, et al.: Factors affecting self-efficacy and pain intensity in patients with chronic musculoskeletal pain seen in a specialist rheumatology pain clinic. Rheumatology 2008, 47:1803-1808.
18. Braden JB, Sullivan MD: Suicidal thoughts and behavior among adults with self-reported pain conditions in the national comorbidity survey replication. J Pain 2008, 9:1106-1115.
19. Ilgen MA, Zivin K, McCammon RJ, et al.: Pain and suicidal thoughts, plans and attempts in the United States. Gen Hosp Psychiatry 2008, 30:521-527.
20. Kroenke K, Shen J, Oxman TE, et al.: Impact of pain on the outcomes of depression treatment: Results from the RESPECT trial. Pain 2008, 134:209-215.
21. Lin EH, Katon W, Von Korff M, et al.: Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA 2003, 290:2428-2429.
22. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al.: Differentiating antidepressants of the future: Efficacy and safety. Pharmacol Ther 2007, 113:134-153.
23. McWilliams LA, Cox BJ, Enns MW: Mood and anxiety disorders associated with chronic pain: An examination in a nationally representative sample. Pain 2003, 106:127-133.
24. Breslau N, Davis GC: Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res 1993, 27:211-221.
25. Dammen T, Ekeberg O, Arnesen H, et al.: Health-related quality of life in non-cardiac chest pain patients with and without panic disorder. Int J Psychiatry Med 2008, 38:271-286.
26. Liebschutz J, Saitz R, Brower V, et al.: PTSD in urban primary care: high prevalence and low physician recognition. J Gen Intern Med 2007, 22:719-726.
27. Jenewein J, Moergeli H, Wittmann L, et al.: Development of chronic pain following severe accidental injury. Results of a 3-year follow-up study. J Psychosom Res 2009, 66:119-126.
28. Bair MJ, Wu J, Damush TM, et al.: Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008, 70:890-897.
29. Clark MR, Chodynicki MP: Pain management. In Textbook of Psychosomatic Medicine. Edited by Levenson JL. Arlington, VA: American Psychiatric Publishing; 2005:827-867.
30. Grabe HJ, Meyer C, Hapke U, et al.: Somatoform pain disorder in the general population. Psychother Psychosom 2003, 72:88-94.
31. Streltzer J, Eliashof BA, Kline AE, et al.: Chronic pain disorder following physical injury. Psychosomatics 2000, 41:227-234.
32. Valet M, Gundel H, Sprenger T, et al.: Patients with pain disorder show gray-matter loss in pain-processing structures: A voxel-based morphometric study. Psychosom Med 2009, 71:49-56.
33. Jackson JL, Kroenke K: Prevalence, impact, and prognosis of multisomatoform disorder in primary care: A 5-year follow-up study. Psychosom Med 2008, 70:430-434.
34. Harris AM, Orav EJ, Bates DW, et al.: Somatization increases disability independent of comorbidity. J Gen Intern Med 2009, 24:155-161.
35. Noyes R Jr, Stuart SP, Watson DB: A reconceptualization of the somatoform disorders. Psychosomatics 2008, 49:14-22.
36. Cicero TJ, Dart RC, Inciardi JA, et al.: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addictionrelated surveillance (RADARS). Pain Med 2007, 8:157-170.
37. McCracken LM, Hoskins J, Eccleston C: Concerns about medication and medication use in chronic pain. J Pain 2006, 7:726-734.
38. Peles E, Schreiber S, Gordon J, et al.: Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain 2005, 113:340-346.
39. Rosenblum A, Joseph H, Fong C, et al.: Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003, 289:2370-2378.
40. Passik SD, Hays L, Eisner N, et al.: Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006, 20:5-13.
41. Clark MR, Stoller KB, Brooner KB: Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry 2008, 53:496-508.
42. Moulin DE, Clark AJ, Gilron I, et al.: Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007, 12:13-21.
43. Dworkin RH, O'Connor AB, Backonja M, et al.: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007, 132:237-251.
44. Gilron I, Bailey J, Weaver DF, et al.: Patients' attitudes and prior treatments in neuropathic pain: A pilot study. Pain Res Manag 2002, 7:199-203.
45. Verdu B, Decosterd I, Buclin T, et al.: Antidepressants for the treatment of chronic pain. Drugs 2008, 68:2611-2632.
46. McCleane G: Antidepressants as analgesics. CNS Drugs 2008, 22:139-156.
47. Dick IE, Brochu RM, Purohit Y, et al.: Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 2007, 8:315-324.
48. Hauser W, Bernardy K, Uceyler N, et al.: Treatment of fibromyalgia syndromes with antidepressants: A meta-analysis. JAMA 2009, 301:198-209.
49. Berger A, Dukes EM, Edelsberg J, et al.: Use of tricyclic antidepressants in older patients with painful neuropathies. Eur J Clin Pharmacol 2006, 62:757-764.
50. Cepeda MS, Farrar JT: Economic evaluation of oral treatments for neuropathic pain. J Pain 2006, 7:119-128.
51. Berrocoso E, Mico JA: Role of serotonin 5-HT1A receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice. Int J Neuropsychopharmacol 2008, 14:1-11.
52. Jones CK, Eastwood BJ, Need AB, et al.: Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 2006, 51:1172-1180.
53. Yucel A, Ozyalcin S, Koknel TG, et al.: The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: A double blind, placebo controlled study. Eur J Pain 2005, 9:407-416.
54. Rowbotham MC, Goli V, Kunz NR, et al.: Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004, 110:697-706.
55. Wernicke JF, Pritchett YL, D'souza DN, et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411-1420.
56. Ziegler D, Pritchett YL, Wang F, et al.: Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007, 30:664-669.
57. Perahia DG, Pritchett YL, Desaiah D, et al.: Efficacy of duloxetine in painful symptoms: An analgesic or antidepressant effect? Int Clin Psychopharmacol 2006, 21:311-317.
58. Moja PL, Cusi C, Sterzi RR, et al.: Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005: CD002919.
59. Tack J, Broekaert D, Fischler B, et al.: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006, 55:1095-1103.
60. Aragona M, Bancheri L, Perinelli D, et al.: Randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain 2005, 9:33-38.
61. Giannopoulos S, Kosmidou M, Sarmas I, et al.: Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. Clin J Pain 2007, 23:267-269.
62. Stefan H, Feuerstein TJ: Novel anticonvulsant drugs. Pharmacol Ther 2007, 113:165-183.
63. Taylor CP, Angelotti T, Fauman E: Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007, 73:137-150.
64. Tanabe M, Takasu K, Takeuchi Y, et al.: Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury. J Neurosci Res 2008, 86:3258-3264.
65. TassonA DM, Boyce E, Guyer J, et al.: Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007, 29:26-48.
66. Tarride JE, Gordon A, Vera-Llonch M, et al.: Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clin Ther 2006, 28:1922-1934.
67. Stacey BR, Barrett JA, Whalen E, et al.: Pregabalin for postherpetic neuralgia: Placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008, 9:1006-1017.
68. Wiffen PJ, Rees J: Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev 2007:CD006044.
69. Vinik AI, Tuchman M, Safirstein B, et al.: Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain 2007, 128:169-179.
70. Van Passel L, Arif H, Hirsch LJ: Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother 2006, 6:19-31.
71. Nasreddine W, Beydoun A: Oxcarbazepine in neuropathic pain. Expert Opin Investig Drugs 2007, 16:1615-1625.
72. Todorov AA, Kolchev CB, Todorov AB: Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 2005, 21:358-361.
73. KotharR SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008, 4:493-506.
74. Munro G, Erichsen HK, Mirza NR: Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology 2007, 53:609-618.
75. BeyreuAher BK, Freitag J, Heers C, et al.: Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
76. Solaro C, Messmer Uccelli M, Uccelli A, et al.: Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol 2000, 44:45-48.
77. Codd EE, Martinez RP, Molino L, et al.: Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain 2008, 134:254-262.
78. Vuckovic SM, Tomic MA, Stepanovic-Petrovic RM, et al.: The effects of alpha2-adrenoceptor agents on anti-hyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory pain. Pain 2006, 125:10-19.
79. Fishbain DA, Cutler RB, Lewis J, et al.: Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review. Pain Med 2004, 5:359-365.
80. Seidel S, Aigner M, Ossege M, et al.: Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2008:CD004844.
81. Wood PB, Schweinhardt P, Jaeger E, et al.: Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007, 25:3576-3582.